Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,307.66
    -2,789.43 (-3.24%)
     

  • CMC Crypto 200

    1,261.38
    -96.63 (-7.12%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

CareDx Wins $44.9 Million in Damages in False Advertising Trial

Investing.com
·1 min read

By Sam Boughedda

Investing.com -- Caredx Inc (NASDAQ:CDNA) announced Monday evening that the company has won its false advertising case against Natera Inc (NASDAQ:NTRA).

CareDx won $44.9 million in damages. Shares rose 8.8% after the announcement.

The jury determined that Natera intentionally misled the transplant community by engaging in false advertising and promoting its Prospera kidney transplant rejection assessment test.

CareDx was awarded $21.2 million compensatory damages and $23.7 million punitive damages. CareDx said "overwhelming evidence" emerged that Natera's senior executives knew of the unscientific and unreliable statements made to market Prospera.

ADVERTISEMENT

"The jury found Natera liable for false advertising based on Natera's false comparisons of its kidney transplant assessment test, Prospera, to CareDx's market-leading AlloSure technology," CareDx said in its press release.

Natera stock is down 16%.

Related Articles

CareDx Wins $44.9 Million in Damages in False Advertising Trial

U.S. senators urge probe of Live Nation's 'exorbitant fees' for tickets

Lilly, Novartis join drugmakers in scaling back operations in Russia